Concentrix Corporation (CNXC)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 4 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $68.75, which forecasts a 46.00% increase in the stock price over the next year. The lowest target is $61 and the highest is $80.

Price Target: $68.75 (+46.00%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$61	$68.75	$72	$80
Change	+29.54%	+46.00%	+52.90%	+69.89%

* Price targets were last updated on Jun 30, 2025.

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	1	1	1	1	1	1
Buy	3	3	3	3	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Vafi Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $80	Strong Buy	Maintains	$80	+69.89%	Jun 30, 2025
Ruplu Bhattacharya B of A Securities	B of A Securities	Hold Maintains $65 → $61	Hold	Maintains	$65 → $61	+29.54%	Jun 27, 2025
Vincent Colicchio Barrington Research	Barrington Research	Buy Maintains $54 → $62	Buy	Maintains	$54 → $62	+31.66%	Jun 27, 2025
David Koning Baird	Baird	Buy Maintains $62 → $72	Buy	Maintains	$62 → $72	+52.90%	Jun 26, 2025
Vincent Colicchio Barrington Research	Barrington Research	Buy Maintains $54	Buy	Maintains	$54	+14.67%	Jun 24, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

9.97B

Increased by 3.66%

from 9.62B

Revenue Next Year

10.29B

Increased by 3.20%

from 9.97B

EPS This Year

11.87

Increased by 219.57%

from 3.71

EPS Next Year

12.63

Increased by 6.43%

from 11.87

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Nov 30, 2020	Nov 30, 2021	Nov 30, 2022	Nov 30, 2023	Nov 30, 2024	Nov 30, 2025	Nov 30, 2026	Nov 30, 2027
Revenue	4.72B	5.59B	6.32B	7.11B	9.62B	9.97B	10.29B	10.66B
Revenue Growth	0.25%	18.38%	13.20%	12.50%	35.20%	3.66%	3.20%	3.57%
EPS	3.19	7.70	8.28	5.70	3.71	11.87	12.63	13.23
EPS Growth	40.53%	141.45%	7.52%	-31.17%	-34.83%	219.57%	6.43%	4.72%
Forward PE	-	-	-	-	-	3.97	3.73	3.56
No. Analysts	-	-	-	-	-	8	8	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	10.3B	10.8B	11.0B
Avg	10.0B	10.3B	10.7B
Low	9.5B	9.7B	10.2B

Revenue Growth

Revenue Growth	2025	2026	2027
High	7.1%	8.0%	7.2%
Avg	3.7%	3.2%	3.6%
Low	-0.9%	-2.7%	-1.1%

EPS Forecast

EPS	2025	2026	2027
High	12.29	13.29	13.62
Avg	11.87	12.63	13.23
Low	11.33	11.68	12.71

EPS Growth

EPS Growth	2025	2026	2027
High	230.7%	12.0%	7.8%
Avg	219.6%	6.4%	4.7%
Low	205.0%	-1.6%	0.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.